Baumal Caroline
Insider CIK 1961100 · APLS Chief Medical Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 49,000 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 37,000 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 82,500 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 26,396 | — | $0 | 26,396 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 12,723 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 8,888 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 26,396 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 29,696 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 41,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 86,525 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | G Gift | 2026-04-29 | 2026-05-01 | 900 | — | $0 | 86,525 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-22 | 2026-01-23 | 2,797 | $21.77 | $60.9K | 86,527 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-20 | 2026-01-21 | 1,882 | $19.79 | $37.2K | 89,324 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-05 | 2026-01-06 | 3,020 | $25.53 | $77.1K | 91,206 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2025-06-09 | 2025-06-11 | 82,500 | $19.39 | $1.60M | 82,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2025-01-21 | 2025-01-21 | 39,594 | — | $0 | 93,301 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-17 | 2025-01-21 | 1,853 | $29.96 | $55.5K | 53,707 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-06 | 2025-01-08 | 2,816 | $33.81 | $95.2K | 55,560 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2024-01-16 | 2024-01-17 | 37,000 | $66.30 | $2.45M | 37,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2024-01-16 | 2024-01-17 | 25,445 | — | $0 | 58,376 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-04 | 2024-01-05 | 2,751 | $60.05 | $165.2K | 32,931 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-01-03 | 2023-01-05 | 49,000 | $50.28 | $2.46M | 49,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-01-03 | 2023-01-05 | 35,549 | — | $0 | 35,682 | SEC↗ |